Tonix Pharmaceuticals Says A Study Published In The Journal Nature By Center For Transplantation Sciences Faculty, Massachusetts General Hospital And Egenesis, Utilized TNX-1500 As Part Of Immune Modulating Regimen To Prevent Organ Transplant Rejection
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals announced that a study published in the Journal Nature by Center for Transplantation Sciences Faculty, Massachusetts General Hospital and Egenesis, utilized TNX-1500 as part of immune modulating regimen to prevent organ transplant rejection.
October 18, 2023 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' TNX-1500 was used in a study to prevent organ transplant rejection, potentially indicating a positive development for the company's product pipeline.
The use of Tonix Pharmaceuticals' TNX-1500 in a study published in a reputable journal indicates recognition and potential effectiveness of the drug. This could lead to increased interest and investment in the company, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100